Natural cancer killers: ASU Biodesign researcher enhances ability of immune system

Cancer remains a leading cause of death globally and is the focus of exhaustive and varied medical research. Many of Arizona State University’s Biodesign Institute researchers are working to establish alternative therapies that sidestep the harmful effects of chemotherapy and radiation while improving the success rate for the more difficult-to-treat cancers.Continue reading

bioSyntagma Awarded “Best Oncology-Focused Precision Medicine Company 2018″

bioSyntagma has been awarded “Best Oncology-Focused Precision Medicine Company 2018” by Global Health and Pharma, a UK-based publication that recognizes global companies for improving public health, enhancing patient care, and lowering healthcare costs.  This award follows several commercial milestones with strategic partners and Big Pharma using bioSyntagma’s beta-instruments to offer biomarker discovery services.Continue reading